Contineum Therapeutics (CTNM) Institutional Ownership $13.50 +0.15 (+1.12%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Contineum Therapeutics (NASDAQ:CTNM)Number ofInstitutional Buyers(last 12 months)13TotalInstitutional Inflows(last 12 months)$106.60MNumber ofInstitutional Sellers(last 12 months)3TotalInstitutional Outflows(last 12 months)$7.07M Get CTNM Insider Trade Alerts Want to know when executives and insiders are buying or selling Contineum Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CTNM Institutional Buying and Selling by Quarter Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Contineum Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/27/2024 Franklin Resources Inc.1,447,550$27.71M0.0%+130.9%5.615% 11/19/2024 Barclays PLC8,308$158K0.0%+248.6%0.032% 11/16/2024 Geode Capital Management LLC128,676$2.46M0.0%-17.7%0.500% 11/15/2024 Barclays PLC8,308$158K0.0%+248.6%0.032% 11/15/2024 State Street Corp113,566$2.17M0.0%+23.7%0.442% 11/14/2024 Suvretta Capital Management LLC1,720,000$32.92M1.1%-16.2%6.687% 11/13/2024 BNP Paribas Financial Markets6,743$129K0.0%+1,248.6%0.026% 11/13/2024 FMR LLC696,927$13.34M0.0%+115.4%2.710% 11/12/2024 Charles Schwab Investment Management Inc.43,295$829K0.0%-16.4%0.168% 8/16/2024 Perceptive Advisors LLC1,566,668$27.59M0.7%N/A6.091% 8/16/2024 Driehaus Capital Management LLC66,667$1.17M0.0%N/A0.259% 8/14/2024 Squarepoint Ops LLC150,000$2.64M0.0%N/A0.583% 8/14/2024 Sandia Investment Management LP5,000$88K0.1%N/A0.019% 8/9/2024 Johnson & Johnson1,979,173$34.85M8.7%N/A7.694% 8/8/2024 Versant Venture Management LLC918,163$16.17M20.9%N/A3.569% 8/1/2024 Rhumbline Advisers6,722$118K0.0%N/A0.026% 7/26/2024 Bank of New York Mellon Corp20,232$356K0.0%N/A0.079% (Data available from 1/1/2016 forward) CTNM Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CTNM shares? During the previous two years, 16 institutional investors and hedge funds held shares of Contineum Therapeutics. The most heavily invested institutionals were Johnson & Johnson ($34.85M), Suvretta Capital Management LLC ($32.92M), Franklin Resources Inc. ($27.71M), Perceptive Advisors LLC ($27.59M), Versant Venture Management LLC ($16.17M), FMR LLC ($13.34M), and Squarepoint Ops LLC ($2.64M).Learn more on CTNM's institutional investors. Which institutional investors have been buying Contineum Therapeutics stock? Of the 13 institutional investors that purchased Contineum Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Johnson & Johnson ($1.98M), Perceptive Advisors LLC ($1.57M), Versant Venture Management LLC ($918.16K), Franklin Resources Inc. ($820.54K), FMR LLC ($373.33K), Squarepoint Ops LLC ($150K), and Driehaus Capital Management LLC ($66.67K). How much institutional buying is happening at Contineum Therapeutics? Institutional investors have bought a total of 5,946,347 shares in the last 24 months. This purchase volume represents approximately $106.60M in transactions. Which Contineum Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Contineum Therapeutics stock in the last 24 months: Suvretta Capital Management LLC ($333.33K), Geode Capital Management LLC ($27.75K), and Charles Schwab Investment Management Inc. ($8.48K). How much institutional selling is happening at Contineum Therapeutics? Institutional investors have sold a total of 369,556 shares in the last 24 months. This volume of shares sold represents approximately $7.07M in transactions. Related Companies MESO Institutional Ownership TVTX Institutional Ownership NTLA Institutional Ownership PRAX Institutional Ownership ARVN Institutional Ownership ARDX Institutional Ownership DAWN Institutional Ownership SYRE Institutional Ownership CALT Institutional Ownership SNDX Institutional Ownership This page (NASDAQ:CTNM) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
